BOCI raised the target price for Wuxi Bio (02269) to HKD37 from HKD31 and maintained the "buy" rating.
The research house said it forecasts WuXi Bio to deliver revenue growth of 16%/15% YoY in FY26/FY27.
【你點睇？】美伊於巴基斯坦恢復談判，你認為美伊衝突會否演變為長期對峙？你認為在現時壓力下，伊朗可維持對抗多久？ ► 立即投票
